How to Decrease Hematocrit in Patients on Testosterone Replacement Therapy

Elevated hematocrit is one of the most common — and most misunderstood — complications of testosterone replacement therapy (TRT).

In many practices, the response is automatic:
“Donate blood.”
“Schedule routine phlebotomy.”
“Stop testosterone.”

While phlebotomy has a role in select situations, routine blood removal treats the consequence, not the cause. In most cases, testosterone-induced erythrocytosis is predictable, preventable, and reversible with proper protocol design.

This article outlines a stepwise, evidence-based approach to lowering hematocrit in men on TRT — without defaulting to phlebotomy — by addressing the real physiologic drivers.

---

Understanding TRT-Induced Erythrocytosis

Testosterone increases red blood cell production through several mechanisms:

• Stimulation of erythropoietin (EPO)

• Suppression of hepcidin, increasing iron availability

• Amplification of erythropoiesis in hypoxic states

• Peak-dependent bone marrow signaling

This effect is dose-, peak-, and oxygenation-dependent, not random and not inevitable.

---

What Hematocrit Actually Measures

Hematocrit (Hct) represents the percentage of blood volume occupied by red blood cells. It does not measure blood thickness directly, but higher values correlate with:

• Increased viscosity

• Reduced microvascular flow

• Higher thrombotic risk at extremes

Importantly, hematocrit elevation is not binary. Trends, rate of rise, symptoms, and context matter.

---

Evidence-Based Ways to Reduce Hematocrit Without Phlebotomy

1. Change the Testosterone Delivery Method (Most Effective Intervention)

The single most effective way to lower hematocrit is to reduce peak testosterone exposure.

Risk of Erythrocytosis by Formulation (Highest → Lowest)

1. Intramuscular testosterone cypionate or enanthate

2. Subcutaneous injections

3. Transdermal gels or creams

4. Pellets (variable, often lower peaks but longer exposure)

Why This Works

• High serum testosterone peaks strongly stimulate EPO

• Lower, smoother delivery reduces marrow signaling

• Erythropoiesis is peak-driven, not trough-driven

Actionable Options

• Switch IM injections → subcutaneous injections

• Divide weekly IM dosing into 2–3 smaller doses

• Transition IM → topical therapy if tolerated

📌 This change alone often lowers hematocrit by 2–5 percentage points.

---

2. Lower the Dose (Even Slightly)

Many men on TRT are supra-physiologic at peak, even when trough levels appear “normal.”

Key Points

• Peak levels drive erythropoiesis

• A 10–20% dose reduction often normalizes hematocrit

• “High-normal at peak” is not physiologic

Best Practice

• Aim for physiologic exposure across the dosing interval

• Combine dose reduction with divided dosing for maximal effect

Small adjustments often produce outsized hematologic improvements.

---

3. Treat Occult Hypoxia (Massively Underappreciated)

This is one of the most missed contributors to TRT-associated erythrocytosis.

Common Sources of Hypoxia

• Obstructive sleep apnea (OSA)

• Chronic nasal obstruction

• Smoking or vaping

• COPD or restrictive lung disease

• High altitude exposure

Testosterone amplifies erythropoiesis in hypoxic states. In these patients, hematocrit elevation is not testosterone excess — it is compensatory physiology.

📌 Treating sleep apnea alone frequently normalizes hematocrit without changing testosterone dose.

---

4. Address Hydration and Plasma Volume

Not all elevated hematocrit represents true polycythemia.

Relative Polycythemia Is Common

• Dehydration

• Diuretic use

• Excess caffeine

• Alcohol intake

Practical Steps

• Encourage consistent hydration

• Recheck CBC when euvolemic

• Avoid interpreting isolated labs during illness or dehydration

This simple step prevents unnecessary intervention.

---

5. Optimize Iron Handling (Advanced but Effective)

Testosterone suppresses hepcidin, increasing iron absorption and availability for erythropoiesis.

Helpful Strategies

• Avoid unnecessary iron supplementation

• Avoid vitamin C with iron-rich meals

• Monitor ferritin to avoid deficiency

This approach stabilizes trends but will not correct severe erythrocytosis alone.

---

6. Angiotensin Receptor Blocker (ARB) Therapy

(Off-label, but physiologically sound)

Angiotensin II directly stimulates erythropoiesis and EPO signaling.

What ARBs Do

Medications such as losartan have been shown to:

• Reduce EPO signaling

• Modestly lower hematocrit

• Improve endothelial function

Best Use Cases

• Patients with hypertension

• Borderline hematocrit elevations despite optimization

• Patients already meeting criteria for antihypertensive therapy

📌 ARBs are not first-line for erythrocytosis, but they are clinically useful adjuncts.

---

7. Aspirin Is NOT the Solution

This is a critical misconception.

What Aspirin Does Not Do

• Aspirin does not lower hematocrit

• It does not correct erythrocytosis

• It does not address the underlying mechanism

While aspirin may reduce platelet aggregation, evidence supporting routine use in TRT-induced erythrocytosis is weak, and bleeding risk increases.

📌 Aspirin should never be used as a substitute for correcting the cause.

---

When Phlebotomy Is Appropriate

Phlebotomy still has a role in specific situations.

Appropriate Indications

• Hematocrit ≥54–55%

• Symptoms of hyperviscosity

• Rapid rise despite optimization

• Temporary bridge while correcting root causes

Why Routine Phlebotomy Is Problematic

• Induces iron deficiency

• Worsens fatigue

• Can perpetuate erythropoiesis via rebound mechanisms

• Masks poor protocol design

Phlebotomy should be rescue therapy, not default management.

---

A Practical Stepwise Approach

Here is a rational sequence that works in most patients:

1. Confirm true elevation (hydration, repeat CBC)

2. Screen for sleep apnea or hypoxia

3. Switch IM → subcutaneous or divide dosing

4. Modestly reduce dose if needed

5. Consider ARB therapy when appropriate

6. Reserve phlebotomy for rescue situations

---

Bottom Line

TRT-induced erythrocytosis is:

• Dose-driven

• Peak-driven

• Hypoxia-amplified

If you control peaks and oxygenation, hematocrit usually follows.

Phlebotomy treats the consequence.
Smart protocol design treats the cause.

---

Scientific References

1. Bachman E, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin. J Gerontol A Biol Sci Med Sci.

2. Coviello AD, et al. Secondary erythrocytosis associated with testosterone therapy. J Clin Endocrinol Metab.

3. Pastuszak AW, et al. Erythrocytosis following testosterone therapy. Sex Med Rev.

4. Calof OM, et al. Adverse events associated with testosterone replacement in older men. J Gerontol A.

5. Moser M, et al. Angiotensin II and erythropoiesis. Hypertension.

6. Marin JM, et al. Effect of CPAP treatment on hematocrit in sleep apnea. Eur Respir J.